The combination of ginsenosides in ginseng extracts may be important for providing more powerful therapeutic and pharmacological effects [15], [16] and [17]. Notably, ginsenoside Rg3

provides various protective effects, including anti-inflammatory [18] and antitumor effects [19], and it also enhances NO production and eNOS activity [20]. The aim of this study was to investigate whether Rg3-enriched Korean Red Ginseng (REKRG), a ginsenoside fraction enriched in Rg3, increases eNOS activity and NO production and exhibits anti-inflammatory effects. Dried Korean Red Ginseng (P. ginseng) root was purchased from Gumsan Nonghyup (Gumsan, Korea). Korean ginseng was extracted two times with 10 volumes of ethanol at 50°C for 7 hours (1st selleck kinase inhibitor 50%, 2nd 85%), and then concentrated under vacuum at 50°C. The crude extract was dissolved in water and enzyme-acid hydrolysis to maximize ginsenoside Rg3 was performed (raw ginsenoside was hydrolyzed to Rg3) in acidic (pH 2.5∼3.5) and thermophilic (65∼80°C) condition. The enzyme, which has β-glycosidase activity including cellulase, hemicellulose,

Everolimus solubility dmso and glucosidase activity, was produced by Aspergillus niger. To remove acid solution and concentrate Rg3, the reactant was passed through DIAION HP20 resin (Mitsubishi Chemical Industries, Tokyo, Japan) packed column. The ginsenoside Rg3 was concentrated to powder under vacuum conditions. It was kindly provided by BTGin Corporation (Occheon, Korea). The powder was dissolved in 70% methanol, and ginsenosides including Rg3 was analyzed by high-performance liquid chromatography (HPLC). HPLC was carried out on an Liquid chromatography (LC) system equipped with a quaternary gradient pump (Spectra 4000) and UV detector (Spectra buy Cetuximab 2000; Thermo Scientific, San Jose, CA, USA). A reversed-phase column (Hypersil gold C18,

100 mm 4.6 mm, internal diameter 5 μm; Thermo Scientific) was used for quantitative determination of ginsenosides Rg3. The mobile phase consisted of acetonitrile and water with a flow rate at 1.6–2.5 mL/min, and the column was kept at room temperature. The detection wavelength was set at 203 nm. Human umbilical vein endothelial cells (HUVECs) were purchased from Clonetics (San Diego, CA, USA) and cultured in Endothelial Growth Medium-2 from Lonza (Walkersville, MD, USA). Subconfluent, proliferating HUVECs were used between passages 2 and 8. The Animal Care Committee of Chungnam National University approved the animal care and all experimental procedures conducted in this study. All instrumentation was used under aseptic conditions. Male Wistar rats and spontaneously hypertensive rats (SHRs; 3 months old) were each divided into two groups (n = 5) randomly: a normal saline group and a REKRG group. REKRG (10 mg/kg) was orally administered to animals for 6 weeks. Anti-ICAM-1, anti-eNOS, and anti-COX-2 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).